Evidence and Context of Use for Contrast Enhancement As a Surrogate of Disease Burden and Treatment Response in Malignant Glioma

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2017 Oct 18

PMID 29040703

Citations 38

Authors

Benjamin M Ellingson

Patrick Y Wen

Timothy F Cloughesy

Affiliations

Soon will be listed here.

Abstract

The use of contrast enhancement within the brain on CT or MRI has been the gold standard for diagnosis and therapeutic response assessment in malignant gliomas for decades. The use of contrast enhancing tumor size, however, remains controversial as a tool for accurately diagnosing and assessing treatment efficacy in malignant gliomas, particularly in the current, quickly evolving therapeutic landscape. The current article consolidates overwhelming evidence from hundreds of studies in the field of neuro-oncology, providing the necessary evidence base and specific contexts of use for consideration of contrast enhancing tumor size as an appropriate surrogate biomarker for disease burden and as a tool for measuring treatment response in malignant glioma, including glioblastoma.

Citing Articles

Editorial: Updates on the management of glioblastoma.

Lubanska D, Hassan S, Porter L, Soliman M Front Oncol. 2025; 15:1526669.

PMID: 39975591 PMC: 11835942. DOI: 10.3389/fonc.2025.1526669.

Surgical identification of brain tumour margins through impedance monitoring and electrocorticography and the potential for their combined use: A systematic review.

Georgiannakis A, Chapman C, Paraskevopoulos D Neurosurg Rev. 2024; 47(1):888.

PMID: 39638915 PMC: 11621190. DOI: 10.1007/s10143-024-03134-0.

1H-MRS parameters in non-enhancing peritumoral regions can predict the recurrence of glioblastoma.

Lu W, Feng J, Zou Y, Liu Y, Gao P, Zhao Y Sci Rep. 2024; 14(1):29258.

PMID: 39587278 PMC: 11589107. DOI: 10.1038/s41598-024-80610-z.

Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.

Oshima S, Yao J, Bobholz S, Nagaraj R, Raymond C, Teraishi A CNS Oncol. 2024; 13(1):2415285.

PMID: 39535237 PMC: 11562955. DOI: 10.1080/20450907.2024.2415285.

A novel methodology for mapping interstitial fluid dynamics in murine brain tumors using DCE-MRI.

Carman-Esparza C, Kingsmore K, Vaccari A, Davis S, Cunningham J, Wang M Methods. 2024; 231:78-93.

PMID: 39284430 PMC: 11851864. DOI: 10.1016/j.ymeth.2024.09.008.

References

Amundsen P, Dugstad G, Syvertsen A . The reliability of computer tomography for the diagnosis and differential diagnosis of meningiomas, gliomas, and brain metastases. Acta Neurochir (Wien). 1978; 41(1-3):177-90. DOI: 10.1007/BF01809148. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Ellingson B, Chung C, Pope W, Boxerman J, Kaufmann T . Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017; 134(3):495-504. PMC: 7893814. DOI: 10.1007/s11060-017-2375-2. View

Coburger J, Hagel V, Wirtz C, Konig R . Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival. PLoS One. 2015; 10(6):e0131872. PMC: 4482740. DOI: 10.1371/journal.pone.0131872. View

Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

Laws E, Parney I, Huang W, Anderson F, Morris A, Asher A . Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003; 99(3):467-73. DOI: 10.3171/jns.2003.99.3.0467. View

Bloch O, Han S, Cha S, Sun M, Aghi M, McDermott M . Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012; 117(6):1032-8. DOI: 10.3171/2012.9.JNS12504. View

Reardon D, Quinn J, Vredenburgh J, Gururangan S, Friedman A, Desjardins A . Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006; 12(3 Pt 1):860-8. DOI: 10.1158/1078-0432.CCR-05-2215. View

Reardon D, Quinn J, Rich J, Desjardins A, Vredenburgh J, Gururangan S . Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005; 104(7):1478-86. DOI: 10.1002/cncr.21316. View

10.

Ramakrishna R, Barber J, Kennedy G, Rizvi A, Goodkin R, Winn R . Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival. Surg Neurol Int. 2010; 1. PMC: 2940100. DOI: 10.4103/2152-7806.68337. View

11.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

12.

Gerstner E, Ye X, Duda D, Levine M, Mikkelsen T, Kaley T . A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015; 17(10):1386-92. PMC: 4578584. DOI: 10.1093/neuonc/nov085. View

13.

Brock C, Newlands E, Wedge S, Bower M, Evans H, Colquhoun I . Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58(19):4363-7. View

14.

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

15.

Reardon D, Fink K, Mikkelsen T, Cloughesy T, ONeill A, Plotkin S . Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26(34):5610-7. DOI: 10.1200/JCO.2008.16.7510. View

16.

Ahmadloo N, Kani A, Mohammadianpanah M, Nasrolahi H, Omidvari S, Mosalaei A . Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst. 2013; 25(1):21-30. DOI: 10.1016/j.jnci.2012.11.001. View

17.

Burger P, Dubois P, Schold Jr S, SMITH Jr K, ODOM G, Crafts D . Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg. 1983; 58(2):159-69. DOI: 10.3171/jns.1983.58.2.0159. View

18.

Badruddoja M, Penne K, Desjardins A, Reardon D, Rich J, Quinn J . Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2006; 9(1):70-4. PMC: 1828104. DOI: 10.1215/15228517-2006-022. View

19.

Murakami R, Hirai T, Nakamura H, Furusawa M, Nakaguchi Y, Uetani H . Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval. Jpn J Radiol. 2011; 30(3):193-7. DOI: 10.1007/s11604-011-0031-x. View

20.

McCullough D, Huang H, DeMichelle D, Manz H, Sinks L . Correlation between volumetric CT imaging and autopsy measurements of glioblastoma size. Comput Tomogr. 1979; 3(2):133-41. DOI: 10.1016/0363-8235(79)90010-3. View